BD MAX Molecular Multi-Drug Resistant Tuberculosis Test to be included in WHO updated consolidated guidelines on TB

April 13, 2021 – BD (Becton, Dickinson and Company) (Franklin Lakes, NJ) announced that its BD MAX Molecular Multi-Drug Resistant Tuberculosis (MDR-TB) Assay was included in the moderate complexity automated NAAT class of molecular diagnostic technologies that were recognized for high diagnostic accuracy for tuberculosis testing by the World Health Organization (WHO) in advance of an update to its guidelines for TB diagnostic tests.

Laboratorians and clinicians can use the BD MAX MDR-TB Assay to simultaneously detect bacteria that cause tuberculosis (TB) and determine if the bacteria contain mutations associated with resistance to two important first-line drugs, isoniazid (INH) and rifampicin (RIF).

The BD MAX MDR-TB Assay is an in vitro diagnostic device with CE mark available in Europe and other countries around the world.

The PCR-based molecular diagnostic test is an integrated diagnostic test intended to help in the detection and diagnosis of TB, and INH and RIF resistance in a single assay.

Learn More